{{Drugbox
| IUPAC_name = 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione
| image = Tiospirone.svg
| width = 275

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Development terminated
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism = Hepatic
| elimination_half-life = 1.4 hours
| excretion = Urine

<!--Identifiers-->
| CAS_number = 87691-91-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 55752
| IUPHAR_ligand = 101
| ChemSpiderID = 50348
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 35C6UMO5SR
| ChEMBL = 35057

<!--Chemical data-->
| C = 24 | H = 32 | N = 4 | O = 2 | S = 1 
| molecular_weight = 440.60 g/mol
}}

'''Tiospirone''' ('''BMY-13,859'''), also sometimes called '''tiaspirone''' or '''tiosperone''', is an [[atypical antipsychotic]] of the [[azapirone]] class.<ref name="pmid2869146">{{cite journal  |vauthors=Yevich JP, New JS, Smith DW, etal | title = Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents | journal = Journal of Medicinal Chemistry | volume = 29 | issue = 3 | pages = 359–69 |date=March 1986 | pmid = 2869146 | doi = 10.1021/jm00153a010| url = }}</ref> It was investigated as a treatment for [[schizophrenia]] in the late 1980s and was found to have an effectiveness equivalent to those of [[typical antipsychotic]]s in [[clinical trial]]s but without causing [[extrapyramidal symptom|extrapyramidal]] [[side effect]]s.<ref name="pmid2885367">{{cite journal |vauthors=Jain AK, Kelwala S, Moore N, Gershon S | title = A controlled clinical trial of tiaspirone in schizophrenia | journal = International Clinical Psychopharmacology | volume = 2 | issue = 2 | pages = 129–33 |date=April 1987 | pmid = 2885367 | doi = 10.1097/00004850-198704000-00006| url = }}</ref><ref name="pmid3294920">{{cite journal |vauthors=Moore NC, Meyendorff E, Yeragani V, LeWitt PA, Gershon S | title = Tiaspirone in schizophrenia | journal = Journal of Clinical Psychopharmacology | volume = 7 | issue = 2 | pages = 98–101 |date=April 1987 | pmid = 3294920 | doi = 10.1097/00004714-198704000-00010| url = }}</ref><ref name="pmid2574893">{{cite journal |vauthors=Borison RL, Sinha D, Haverstock S, McLarnon MC, Diamond BI | title = Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial | journal = Psychopharmacology Bulletin | volume = 25 | issue = 2 | pages = 190–3 | year = 1989 | pmid = 2574893 | doi = | url = }}</ref><ref name="isbn0-88048-681-3">{{cite book |author1=Nasrallah, Henry A. |author2=Shriqui, Christian L | title = Contemporary issues in the treatment of schizophrenia | publisher = American Psychiatric Press | location = Washington, DC | year = 1995 | page = 313 | isbn = 0-88048-681-3 | oclc = | doi = | url = https://books.google.com/books?id=ut79yW-IZx4C&lpg=PA313&dq=tiospirone%20adrenergic&pg=PA313#v=onepage&q=&f=false}}</ref> However, development was halted and it was not marketed. [[Perospirone]], another azapirone derivative with antipsychotic properties, was synthesized and assayed several years after tiospirone.<ref name="pmid8582016">{{cite journal |vauthors=Ishizumi K, Kojima A, Antoku F, Saji I, Yoshigi M | title = Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds | journal = Chemical & Pharmaceutical Bulletin | volume = 43 | issue = 12 | pages = 2139–51 |date=December 1995 | pmid = 8582016 | doi = 10.1248/cpb.43.2139| url = }}</ref> It was found to be both more [[potent (pharmacology)|potent]] and more [[functional selectivity|selective]] in comparison and was commercialized instead.<ref name="pmid8582016"/>

==Pharmacology==

===Pharmacodynamics===
Tiospirone acts as a [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[partial agonist]], [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]] [[inverse agonist]], and [[D2 receptor|D<sub>2</sub>]], [[D4 receptor|D<sub>4</sub>]], and  [[Alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptor]] [[receptor antagonist|antagonist]].<ref name="pmid7766287">{{cite journal  |vauthors=Sumiyoshi T, Suzuki K, Sakamoto H, etal | title = Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy | journal = Neuropsychopharmacology | volume = 12 | issue = 1 | pages = 57–64 |date=February 1995 | pmid = 7766287 |  doi = 10.1016/0893-133X(94)00064-7}}</ref><ref name="pmid8524985">{{cite journal |vauthors=Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY | title = D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs | journal = Psychopharmacology | volume = 120 | issue = 3 | pages = 365–8 |date=August 1995 | pmid = 8524985 | doi = 10.1007/BF02311185| url = }}</ref><ref name="pmid11561089">{{cite journal  |vauthors=Weiner DM, Burstein ES, Nash N, etal | title = 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 299 | issue = 1 | pages = 268–76 |date=October 2001 | pmid = 11561089 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=11561089}}</ref><ref name="pmid10991983">{{cite journal |vauthors=Herrick-Davis K, Grinde E, Teitler M | title = Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 295 | issue = 1 | pages = 226–32 |date=October 2000 | pmid = 10991983 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=10991983}}</ref><ref name="pmid17786406">{{cite journal |vauthors=Rauly-Lestienne I, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Cussac D | title = Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 376 | issue = 1–2 | pages = 93–105 |date=October 2007 | pmid = 17786406 | doi = 10.1007/s00210-007-0182-6 }}</ref><ref name="pmid15707540">{{cite journal |vauthors=Newman-Tancredi A, Assié MB, Leduc N, Ormière AM, Danty N, Cosi C | title = Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia | journal = The International Journal of Neuropsychopharmacology | volume = 8 | issue = 3 | pages = 341–56 |date=September 2005 | pmid = 15707540 | doi = 10.1017/S1461145704005000 | url = http://journals.cambridge.org/abstract_S1461145704005000}}</ref>

'''Binding profile'''<ref>{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) |author1=Roth, BL |author2=Driscol, J | url = http://pdsp.med.unc.edu/pdsp.php | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 3 December 2013 | date = 12 January 2011}}</ref>
{| class = wikitable
! Receptor !! K<sub>i</sub> (nM)
|-
| 5-HT<sub>2A</sub> || 0.06
|-
| 5-HT<sub>2C</sub> || 9.73
|-
| 5-HT<sub>6</sub> || 950
|-
| 5-HT<sub>7</sub> || 0.64
|-
| M<sub>1</sub> || 630
|-
| M<sub>2</sub> || 180
|-
| M<sub>3</sub> || 1290
|-
| M<sub>4</sub> || 480
|-
| M<sub>5</sub> || 3900
|-
| D<sub>2</sub> || 0.5
|-
| D<sub>4</sub> || 13.6
|}

== See also ==
* [[Azapirone]]

== References ==
{{Reflist}}

{{Antipsychotics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Serotonin receptor modulators}}
{{Sigma receptor modulators}}
}}

[[Category:Abandoned drugs]]
[[Category:Antipsychotics]]
[[Category:Azapirones]]
[[Category:Benzothiazoles]]
[[Category:Piperazines]]